Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.73 USD
+0.04 (2.37%)
Updated Oct 15, 2024 03:46 PM ET
After-Market: $1.73 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BRTX 1.73 +0.04(2.37%)
Will BRTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRTX
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for BRTX
BioRestorative Therapies? IFATS 2024 Presentation to Feature ThermoStem? Platform?s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
Buy Rating Affirmed for BioRestorative Therapies Amid Strong Financials and Clinical Progress
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
BioRestorative Therapies Clarifies Press Release Usage in Filings